FluoroPharma is developing breakthrough molecular imaging agents for positron emission tomography (PET) and fluorescence imaging that will fulfill critical unmet medical needs. The Company’s agents will give clinicians important tools for the detection and assessment of pathology before clinical manifestations of coronary disease.
More than 7 million patients in the U.S. are now afflicted with coronary artery disease, and it is thought to account for more than 30 percent of deaths annually.
The current U.S. molecular imaging market represents a $1.3 billion opportunity. PET is rapidly emerging as an accurate and potentially preferred method of assessing myocardial perfusion and metabolism in the evaluation of coronary artery disease. Until recently, 70% of these studies used Tc99m-labeled compounds for both injections in combination with Single Photon Emission tomography (SPECT) imaging.
FluoroPharma’s technology consists of novel molecular PET and optical imaging agents for the cardiovascular, oncology, and neurology arenas.